等待開盤 08-21 09:30:00 美东时间
-0.200
-1.45%
On August 18, 2026, the board of directors (the "Board") of Pilgrim’s Pride Corporation (the "Company") received an unsolicited proposal (the "Proposal") from its majority stockholder JBS N.V. ("JBS") to acquire all of the outstanding shares of common stock of the Company not already owned by JBS or...
08-20 20:29
今日重点评级关注:Canaccord Genuity:维持Cardiol Therapeutics"买入"评级,目标价从8美元升至10美元;B. Riley证券:维持Macrogenics"买入"评级,目标价从9美元升至11美元
08-18 11:39
今日重点评级关注:Canaccord Genuity:维持Sagimet Biosciences"买入"评级,目标价从49美元升至56美元;韦德布什:维持Zura Bio"跑赢大市"评级,目标价从15美元升至22美元
08-13 11:44
JP Morgan analyst Lucas Ferreira maintains JBS (NYSE:JBS) with a Overweight and lowers the price target from $18 to $17.5.
08-12 22:37
华盛资讯8月11日讯,JBS N.V. Class A公布2026财年Q2业绩,公司Q2营收239.00亿美元,同比增长13.8%,归母净利润亏损1.02亿美元,由盈转亏。
08-11 18:39
华盛资讯8月11日讯,JBS N.V. Class A公布2026财年Q2业绩,公司Q2营收239.00亿美元,同比增长13.8%,归母净利润亏损1.02亿美元,由盈转亏。
08-11 05:35
JBS (NYSE:JBS) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $0.32 by 128.13 percent. This is a 118.75 percent decrease over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $23.899 billion which beat ...
08-11 05:24
今日重点评级关注:HC Wainwright & Co.:维持Q32 Bio"买入"评级,目标价从13美元升至36美元;Chardan Capital:维持ProMIS Neurosciences"买入"评级,目标价从20美元升至33美元
07-29 11:37
JP Morgan analyst Lucas Ferreira upgrades JBS (NYSE:JBS) from Neutral to Overweight and maintains the price target from $18 to $18.
07-28 18:45